Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026)
Lineage Cell Therapeutics' Income from Non-Controlling Interests was $62,000 in Q2 2026, down 38.0% from $100,000 a year earlier but up 169.6% from the prior quarter.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Lineage Cell Therapeutics' Income from Non-Controlling Interests was $155,000 through Jun 30, 2026, up 2.0% year-over-year; for FY2025, it was $166,000, up 514.8% from FY2024.
- In earlier years, Income from Non-Controlling Interests was $27,000 in FY2024 (+285.7%), $7,000 in FY2023, -$80,000 in FY2022 and -$251,000 in FY2021.
- Quarterly Income from Non-Controlling Interests has moved between -$200,000 (Q4 2021) and $100,000 (Q2 2025) over five years.
- Compared with a year earlier, Income from Non-Controlling Interests was higher in 1 of the last four quarters, with an average decline of 8.5%.
- Per Business Quant data, LCTX's Income from Non-Controlling Interests in the three quarters before Q2 2026 was $23,000 (Q1 2026), $41,000 (Q4 2025) and $29,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | - |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.00 Mn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -2.00 Mn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -7.00 Mn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 1.00 Mn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | - |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 10.00 Mn |
| 10 | Lineage Cell Therapeutics | 235.20 Mn | 33.61 Mn | - | 62,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -19,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Dec 31, 2021 | -200,000.00 |
| Sep 30, 2021 | -11,000.00 |
API Access
Lineage Cell Therapeutics Income from Non-Controlling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=LCTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "LCTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=LCTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();